Marketplace for digital therapeutics and patient programs (updated June 2021)
Lilo Health collaborates with pharmaceutical companies to co-create specific patient journeys within one central smartphone app aimed at changing behaviours & improving treatment adherence.
What differentiates the company from competitors is the integration of user-friendly remote blood testing, the collection of holistic clinical-grade data, and a connected doctor platform. A compelling USP already generating traction in the fields of cardiovascular health, oncology, and inflammatory diseases for projects across Europe and the US.
Since April, the company has brought in 3,800 free testers (CAC 0.23€) with the relevant profiles (over 60 comorbidities recorded), and is currently bringing in 760 new registrations per week. Our key milestone to reach our next round of investment planned for July 2022 (6-8€m) is the launch and success of our phase 2 studies in Belgium and Germany.
Previously raised 450€k and currently seeking 1.2€m to reach the full benefits from the current traction